Drugs / AJU-A51
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04972539 | Aug → Nov 2020 | type 2 diabetes mellitus | AJU Pharm Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AJU-A51 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04972539 ↗ |
| Route | Oral | “Single oral dose AJU-A51(Dapagliflozin/Linagliptin) 10 mg / 5 mg FDC tablet” NCT04972539 ↗ |